TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of polyarticular juvenile rheumatoid arthritis (JRA) according to the criteria of the American College on Rheumatology (ACR)~* Disease activity inadequately controlled by nonsteroidal anti-inflammatory drugs (NSAIDs) or methotrexate (MTX)~* Presence at screening of at least 5 swollen joints (not due to deformity) and at least 3 joints with limitation of passive motion with pain by passive motion or/and pain by pressure (tenderness)~* Stable dosage of MTX for at least 12 weeks prior to the screening visit or discontinuation of MTX at least 14 days prior to baseline visit (Day 1)~* Discontinuation of disease-modifying antirheumatic drugs (DMARDs) other than MTX at least 28 days before screening visit~Exclusion Criteria~* History of inflammatory joint disease other than JRA~* Functional class IV JRA by ACR criteria~* Clinically significant cardiac disease or laboratory abnormalities~* Any subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- third and fourth degree perineal laceration~Exclusion Criteria:~- chorioamnionitis, HIV positive, inflammatory bowel disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cefotetan, Cefoxitin or Clindamycin (Type: ACTIVE_COMPARATOR): None
- Normal Saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~  * Newly diagnosed disease~ * Symptomatic disease~* Measurable or evaluable disease, defined by ≥ 1 of the following criteria:~  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis~ * Monoclonal protein \> 200 mg by 24-hour urine electrophoresis~ * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio~ * Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)~ * Measurable soft tissue plasmacytoma not previously irradiated~* No monoclonal gammopathy of undetermined significance or smoldering myeloma~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 (ECOG PS 3 allowed if secondary to pain)~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL~* Creatinine ≤ 2.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method contraception (1 highly effective and 1 additional method) for 1 month before, during, and for 4 weeks after completion of study therapy~* No uncontrolled infection~* No other active malignancy~* No other malignancies within the past 5 years except for currently treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast~* No NYHA class III-IV congestive heart failure~* No untreated active deep vein thrombosis~PRIOR CONCURRENT THERAPY:~* At least 3 weeks since prior radiotherapy for solitary plasmacytoma~* Prior clarithromycin, therapeutic dehydroepiandrosterone (DHEA), anakinra, pamidronate disodium, or zoledronic acid allowed~* No prior cytotoxic chemotherapy~* No prior corticosteroids (except for treatment of a nonmalignant disorder)~* Concurrent corticosteroids (prednisone ≤ 20 mg/per day) allowed~* No concurrent radiotherapy except palliative radiotherapy for a single painful bone lesion or fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide/Cyclophosphamide/Dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Currently untreated PNH participants with PNH Type III erythrocyte and/or granulocyte clone size ≥10% and anemia (hemoglobin \<12 grams/deciliter) with adequate reticulocytosis (as determined by the Investigator).~* LDH ≥1.5 x the upper limit of normal.~* Platelets ≥50,000/microliter without the need for platelet transfusions.~* Documentation of vaccination for Neisseria meningitidis, Haemophilus influenza, and Streptococcus pneumoniae, or willingness to receive vaccinations during the screening period.~* Negative pregnancy test for females prior to dosing and throughout the study.~Exclusion Criteria:~* History of a major organ transplant (for example, heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant.~* Participants who had received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater.~* Participants who had received eculizumab at any dose or interval within the past 75 days before study entry.~* Participants with known or suspected complement deficiency.~* Participants with active bacterial infection or clinically significant active viral infection, a body temperature \>38°Celsius, or other evidence of infection on Day 1, or with a history of febrile illness within 14 days prior to first study drug administration.~* History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection.~* Females who were pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration or participants with a female partner who was pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danicopan (Type: EXPERIMENTAL): Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kaletra-isentress Treatment Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1-infected individuals receiving HAART regimen (if on PI-based regimen, must be 1st PI-containing HAART).~* They must have been on and tolerating current HAART regimen for \> 6-months.~* Plasma HIV-1 viral load \< 50 copies/ml at study entry.~* Men and women age \> 18 years (sex is defined as sex at birth).~* Laboratory values obtained within 30 days prior to study entry:~  * Hemoglobin \> 9.4 g/dl~ * Creatinine \< 2 mg/dl~ * AST (SGOT) \< 2 x ULN~ * ALT (SGPT) \< 2 x ULN~* Ability and willingness of subject or legal guardian/representative to give written informed consent.~* No CD4 T-cell counts requirement~Exclusion Criteria:~* Subjects with a history of previous intolerance to or virological failure to LPV/r~* Concomitant drugs (including alternative therapies) that may affect PI or RAL plasma concentrations (inducers or inhibitors of the CYP 3A4 or UDP-glucuronosyltransferase iso-enzymes).~* A known history of noncompliance with medications or a known history of noncompliance with scheduled physician and clinic visits.~* Investigational ARV drug.~* Pregnancy/Breast feeding.~* HBV-coinfected patients receiving nucleoside analogue for both HIV and HBV suppression.~* Active drug or alcohol use or dependence which, in the Investigator's opinion, may interfere with adherence to study requirements or endanger subject's health while on the study.~* Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Kaletra + Isentress (Type: EXPERIMENTAL): Kaletra + Isentress
- Standard HAART (Type: ACTIVE_COMPARATOR): Pre-study Antiretroviral regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Impact of myHealth Rewards Enrollment Emails

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Geisinger employees who are benefits subscribers~Exclusion Criteria:~* Those who had already registered for myHealth Rewards in 2019, up through May 6, 2019~* New Geisinger employees hired between December 1, 2018 and May 6, 2019~* Existing Geisinger employees who transitioned from non-subscribers in 2018 to subscribers in 2019

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No email (Type: None): No email will be sent out to this subset of GHP members during the week that the other emails are sent.
- Standard email reminder (Type: None): The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
- Social norms email (Type: None): The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
- Loss framing (Type: None): The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optical Head-Mounted Display Technology for Low Vision Rehabilitation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for subjects with retinal dystrophy:~* diagnosis of retinal dystrophy~* severe vision loss that constitutes legal blindness~* able to perform a reliable Goldmann visual field test~* constricted visual field less than or equal to 20 degrees by Goldmann perimetry using the III4e stimulus in at least one eye with best-corrected visual acuity ≥ 20/60~Inclusion criteria for control subjects:~* healthy controls~* visit history with the Comprehensive and Pediatric Ophthalmology Services at the University of Michigan~* able to perform a reliable Goldmann visual field test~Exclusion criteria for subjects with retinal dystrophy:~* movement disorder that precludes evaluation of mobility~* functional vision loss~* pregnant women~Exclusion criteria for control subjects:~* visually significant ocular condition other than correctable refractive error~* movement disorder that precludes evaluation of mobility~* functional vision loss~* pregnant women

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Retinal Dystrophy (Type: EXPERIMENTAL): Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
- Healthy Age-Matched Controls (Type: EXPERIMENTAL): Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old.~2. Able to provide informed consent, or have a caregiver able to provide consent~3. Meets the definition of non-severe recurrent CDI (see Section 2.1, above) AND~4. Has had a positive stool test for C. difficile within 60 days of enrolment~5. Able to undergo colonoscopy and enemas~6. Not pregnant~7. Willing to participate in follow up as part of the study~In addition, the patient must agree to undergo stool testing and blood screening tests that are part of the study, including hepatitis and HIV testing~Exclusion Criteria:~1. Life expectancy \< 6 months~2. Evidence of severe CDI ((neutropenia (ANC\<1000) or WBC\>30, creatinine \>2X baseline, presence of toxic megacolon or intestinal perforation, admission to ICU)~3. History of chronic diarrhea~4. Need for regular use of agents that affect GI motility (narcotics such as codeine or morphine, agents such as loperamide or metoclopramide)~5. Use of antibiotics for another infection (other than CDI)~6. Colostomy~7. Elective surgery that will require preoperative antibiotics planned within 6 months of enrolment~8. Pregnant or planning to get pregnant in the next 6 months~9. Unable to tolerate MET-2 for any reason~10. Any condition for which colonoscopy or enema may be contraindicated (e.g., neutropenia, thrombocytopenia, bleeding disorders, severe colitis, etc)~11. Any condition for which, in the opinion of the investigator, the patient should be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MET-2 Capsules (Type: EXPERIMENTAL): Patients will be on vancomycin to control symptoms up until the time of the treatment.~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..~All patients will be followed up for 120 days after the last treatment has been received.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Specificity of Dyspnoea Relief With Inhaled Furosemide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy individuals~Exclusion Criteria:~* On any medication, including herbal medication (other than mild analgesics, vitamins and mineral supplements or, for females, oral contraceptives), whether prescribed or over-the-counter, in the two weeks prior to test sessions involving administration of furosemide or saline.~* Female participants who are pregnant, lactating or planning pregnancy over the course of trial~* A medical history of heart, kidney or liver disease/electrolyte disturbances/ immunosuppression/frequent fainting episodes/COPD/nasal polyps/Addison's/acute porphyria/significant prostatic symptoms/acute gout attack/life expectancy \<6months or history of allergic reaction to furosemide and/or any of the other ingredients of furosemide or amiloride, sulfonamides or sulphonamide derivatives, such as sulfadiazine or co-trimoxazole~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.~* Have participated in another research trial involving an investigational product in the past 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Air Hunger (Type: ACTIVE_COMPARATOR): Previous studies have shown that inhaled furosemide relieves 'air hunger'.~Each volunteer has 3 mists per visit. The mists are either in the order of Furosemide-Saline-Furosemide or Saline-Furosemide-Saline. The furosemide mist is 40mg (10mg/ml) nebulised and the saline mist is 4ml nebulised.~Induced air hunger (hypercapnia with constrained ventilation) is the active comparator and will be the type of breathlessness induced, before and after each mist inhalation on one day. .
- Work Effort (Type: EXPERIMENTAL): Induced sense of breathing effort (raised ventilation with external resistive load) is the 'experimental arm' and will be the type of breathlessness induced, before and after each mist inhalation on the other day. .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Health adults of both genders~* Age ≥ 18 ≤ 50 years~* Able to understand every required study procedure~* Female volunteers should agree to take an acceptable contraceptive method Menopause is characterized by absence of menstrual flux for two consective years~* Normal values for pre-stablished laboratory assays~* Accpetance to participate and sign the consent form~Exclusion Criteria:~* Any chronic condition~* Be on immunossupressive or stimulant therapy~* Have egg alergy~* Have past history of alergy to sazonal influenza vaccine~* Have received another inactivated vaccine within the prior 2 weeks or a live vaccine in the past four weeks to his/her participation in the study~* Acute infectious disease during seven days prior vaccination~* Female on breasthfeeding~* Confirmed prior infection by pandemic influenza A~* Participation in another clinical trial in the last 6 months~* Any other condition identified by the principal investigator which is considered not safe for enrollment of the volunteer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- pandemic vaccine 1 (Type: EXPERIMENTAL): 7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
- pandemic vaccine 2 (Type: EXPERIMENTAL): 3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
- pandemic vaccine 5 (Type: EXPERIMENTAL): 7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
- pandemic vaccine 6 (Type: EXPERIMENTAL): 3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
- pandemic vaccine 9 (Type: EXPERIMENTAL): 7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
- pandemic vaccine 10 (Type: EXPERIMENTAL): 3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
- pandemic vaccine 11 (Type: EXPERIMENTAL): 7,5µg of A/H1N1 with Al(OH)3
- pandemic vaccine 12 (Type: EXPERIMENTAL): 3,75µg of A/H1N1 with Al(OH)3
- pandemic vaccine 13 (Type: EXPERIMENTAL): 15µg of A/H1N1 with no adjuvant
- placebo group 14 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete